MedTrace Logo

CPC-201 Alzheimer's Disease Type Dementia: PET Study

NCT02860065 · Status: WITHDRAWN · Phase: PHASE2 · Type: INTERVENTIONAL

Last updated 2017-08-09

No results posted yet for this study

Summary

The purpose of this study is to compare the effect of low and high dose CPC-201 on brain function including cerebral acetylcholinesterase (AChE) activity measured by positron emission tomography (PET).

Conditions

Interventions

DRUG

CPC-201

solifenacin and donepezil

OTHER

Positron emission tomography (PET)

measure activity of cerebral acetylcholinesterase

Sponsors & Collaborators

  • Chase Pharmaceuticals Corporation, an affiliate of Allergan plc

    lead INDUSTRY

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
50 Years
Max Age
79 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-09-30
Primary Completion
2017-06-30
Completion
2017-06-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02860065 on ClinicalTrials.gov